CL2021001621A1 - Formulaciones orales de branaplam - Google Patents

Formulaciones orales de branaplam

Info

Publication number
CL2021001621A1
CL2021001621A1 CL2021001621A CL2021001621A CL2021001621A1 CL 2021001621 A1 CL2021001621 A1 CL 2021001621A1 CL 2021001621 A CL2021001621 A CL 2021001621A CL 2021001621 A CL2021001621 A CL 2021001621A CL 2021001621 A1 CL2021001621 A1 CL 2021001621A1
Authority
CL
Chile
Prior art keywords
branaplam
oral formulations
tetramethylpiperidin
pyridazin
pyrazol
Prior art date
Application number
CL2021001621A
Other languages
English (en)
Inventor
Rohit Lowalekar
RASPIDE Manaud DE
Thomas Faller
Claire Haug
Gomes Dos Santos Paulo Antonio Fernandes
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021001621A1 publication Critical patent/CL2021001621A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas adecuadas para administración oral que comprenden 5-(1H-pirazol-4-il)-2-(6-((2,2,6,6-tetrametilpiperidin-4-il)oxi)piridazin-3-il)fenol (branaplam) y una ciclodextrina farmacéuticamente aceptable
CL2021001621A 2018-12-21 2021-06-17 Formulaciones orales de branaplam CL2021001621A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201811048667 2018-12-21

Publications (1)

Publication Number Publication Date
CL2021001621A1 true CL2021001621A1 (es) 2022-02-11

Family

ID=69165436

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001621A CL2021001621A1 (es) 2018-12-21 2021-06-17 Formulaciones orales de branaplam

Country Status (14)

Country Link
US (1) US20220071996A1 (es)
EP (1) EP3897576A1 (es)
JP (1) JP2022513976A (es)
KR (1) KR20210107038A (es)
CN (1) CN113226285A (es)
AR (1) AR117719A1 (es)
AU (1) AU2019404930A1 (es)
BR (1) BR112021011744A2 (es)
CA (1) CA3119084A1 (es)
CL (1) CL2021001621A1 (es)
IL (1) IL283593A (es)
MX (1) MX2021007485A (es)
TW (1) TW202038908A (es)
WO (1) WO2020128915A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304446A (zh) * 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
WO2024015518A1 (en) * 2022-07-13 2024-01-18 Inaya Therapeutics, Inc. Inhalable imatinib formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Also Published As

Publication number Publication date
WO2020128915A1 (en) 2020-06-25
CN113226285A (zh) 2021-08-06
TW202038908A (zh) 2020-11-01
IL283593A (en) 2021-07-29
CA3119084A1 (en) 2020-06-25
BR112021011744A2 (pt) 2021-08-31
KR20210107038A (ko) 2021-08-31
MX2021007485A (es) 2021-08-05
JP2022513976A (ja) 2022-02-09
EP3897576A1 (en) 2021-10-27
AU2019404930A1 (en) 2021-06-03
US20220071996A1 (en) 2022-03-10
AR117719A1 (es) 2021-08-25

Similar Documents

Publication Publication Date Title
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CO2019001895A2 (es) Formulación novedosa para administración por vía oral
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CL2021001621A1 (es) Formulaciones orales de branaplam
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
NI201600048A (es) Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
AR099385A1 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
BR112019007858A2 (pt) formulações farmacêuticas e métodos para produzir as mesmas
EA202092829A1 (ru) Композиции тофацитиниба с контролируемым высвобождением
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
CO6640318A2 (es) Formas de dosificación oral de bendamustina
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
PE20151607A1 (es) Formulaciones de compuestos organicos
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
PE20211738A1 (es) Formulacion basada en ciclodextrina de un inhibidor de bcl-2
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
DOP2018000024A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc